Table 3.
Multivariable Logistic Regression Model Predicting Hearing Loss
| Predictors | Adjusted OR (95% CI) | P Value |
|---|---|---|
| Age (years) | 1.04 (1.01–1.08) | .014 |
| BMI (kg/m2) | ||
| <18.5 | 1 (Reference) | |
| 18.5–24.9 | 0.38 (0.18–0.82) | .014 |
| ≥25 | 0.28 (0.09–0.87) | .028 |
| Standardized weekly AG dose (mg/kg/week) | ||
| <60 | 1 (Reference) | |
| 60–74.9 | 0.66 (0.26–1.69) | .386 |
| ≥75 | 1.31 (0.52–3.33) | .569 |
| HIV status and CD4 count (cells/mm3) | ||
| HIV negative | 1 (Reference) | |
| HIV positive with CD4 ≥200 | 1.69 (0.68–4.22) | .261 |
| HIV positive with CD4 <200 | 2.02 (0.82–5.01) | .127 |
| Serum albumin (g/L) | 1.02 (0.97–1.08) | .486 |
| Pre-existing composite hearing lossa | 1.17 (0.55–2.46) | .685 |
| Full model: log odds of hearing loss = 0.045 (age) – 0.96 (BMI: 18.5–24.9) – 1.27 (BMI: ≥25) – 0.41 (weekly AG dose: 60–74.9) + 0.27 (weekly AG dose: ≥75) + 0.53 (HIV+ with CD4 ≥200) + 0.71 (HIV+ with CD4 <200) + 0.02 (serum albumin) + 0.15 (pre-existing composite hearing loss) – 1.61. |
Abbreviations: AG, aminoglycoside; BMI, body mass index; CD4, cluster of differentiation 4; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio.
aPre-existing composite hearing loss defined as confirmed by either audiometry or self-reported auditory symptoms.